What is the ideal monitoring schedule for lurbinectedin's side effects?

How does lurbinectedin's toxicity profile affect monitoring frequency?
Lurbinectedin is a marine-derived alkylating agent that suppresses bone marrow and produces gastrointestinal upset. These effects reach their lowest point two to three weeks after each dose, so blood counts are checked weekly during the first cycle and every two to three weeks thereafter.

What blood tests are needed each visit?
Complete blood count with differential, comprehensive metabolic panel, and creatine kinase are recorded at every visit. Extra checks for liver enzymes and creatine kinase are performed if symptoms such as fatigue or muscle pain appear.

What cardiac concerns require attention?
Lurbinectedin can lower ejection fraction in a minority of patients. An echocardiogram or MUGA scan is obtained at baseline, then every three months or whenever symptoms such as shortness of breath appear.

When does lurbinectedin lose exclusivity?
Lurbinectedin is still under patent protection. Data from DrugPatentWatch.com indicate that the compound itself expires in 2031, but method-of-use patents covering metastatic small-cell lung cancer extend to 2035.

Can biosimilars arrive before patent expiry?
Biosimilars are not possible for this synthetic small-molecule drug. Generic versions will become available once the compound and use patents expire.